## Protic NHC iridium complexes with $\beta$ -H reactivity – synthesis, acetonitrile insertion, and oxidative self-activation

Mark K. Rong,<sup>†</sup> Andrei Chirila,<sup>†</sup> David Franciolus,<sup>†</sup> Martin Lutz,<sup>‡</sup> Martin Nieger,<sup>§</sup> Andreas W. Ehlers,<sup>†</sup>, ||,<sup>⊥</sup> J. Chris Slootweg<sup>\*,†,⊥</sup> and Koop Lammertsma<sup>\*,†,||</sup>

<sup>†</sup> Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands.

<sup>‡</sup> Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.

<sup>§</sup> Department of Chemistry, University of Helsinki, A. I. Virtasen aukio 1, P.O. Box 55, Helsinki, Finland.

Department of Chemistry, Oakland Park 2006, University of Johannesburg, Johannesburg, South Africa.

⊥ Current address: Van 't Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands.

## SUPPORTING INFORMATION

TABLE OF CONTENTS

1. Experimental Details	
2. NMR-spectra	S5
3. Crystal structure determinations	
4. Optimized Structures	

## 1. Experimental Details

### **General considerations**

All experiments were performed under an atmosphere of dry nitrogen using standard Schlenk-line and glovebox techniques, unless stated otherwise. Solvents were distilled under nitrogen over the appropriate drying agent; CaCl<sub>2</sub> (DCM), benzophenone/NaK (Et<sub>2</sub>O, THF), LiAlH<sub>4</sub> (pentane), K<sub>2</sub>CO<sub>3</sub> (MeCN, acetone), P<sub>2</sub>O<sub>5</sub> (CD<sub>2</sub>Cl<sub>2</sub>, CDCl<sub>3</sub>). C<sub>6</sub>D<sub>6</sub> was dried over Na at room temperature. Anhydrous MeOH was obtained from Sigma-Aldrich. Water was degassed ultrasonically under reduced pressure. 2-Azido-phenyl isonitrile (1)<sup>1</sup> was kindly provided by C. A. Dumke and F. E. Hahn.<sup>2</sup> All other reagents were used as received. Solids were predried *in vacuo* for at least 15 min. NMR spectra were recorded on Bruker Avance 400 (<sup>1</sup>H, 400.13 MHz; <sup>13</sup>C (<sup>1</sup>H}), 100.61 MHz, room temperature) or a Bruker Avance 500 (<sup>1</sup>H, 500.23 MHz; <sup>13</sup>C (<sup>1</sup>H}), 125.78 MHz; room temperature). Chemical shifts are reported in ppm downfield from tetramethylsilane. <sup>1</sup>H-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  7.26) and CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  5.32). <sup>13</sup>C-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  7.26) and CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  5.32). <sup>13</sup>C-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  7.26) and CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  5.32). <sup>13</sup>C-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  77.16) and CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  5.384). Melting points were measured using a Büchi Melting Point M-565 (sealed capillaries) and are uncorrected. High resolution electrospray ionization (ESI) mass spectrometry was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Infrared spectra have been recorded on a Shimadzu FT-IR 8400S spectrophotometer.

### (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride dimer<sup>3</sup>

Prepared according to literature procedures.

## 1,3-dimethyl-benzimidazolium iodide4

Prepared according to literature procedures.

### Bis(1,3-dimethylbenzimidazolidin-2-ylidene)<sup>5</sup>

Prepared according to literature procedures.

### (2-azidophenylisonitrile) (1-methyl-4-isopropyl-benzene) ruthenium(II) dichloride<sup>6</sup>

Prepared according to literature procedures.

### (2-azidophenylisonitrile) (1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III) dichloride

[RhCp\*Cl<sub>2</sub>] (94 mg, 0.15 mmol, 1.0 eq.) in DCM (15 mL) was added to 2-azidophenylisonitrile (49 mg, 0.34 mmol, 2.3 eq.) to provide a red solution, which was stirred for 43.5h at RT, in absence of light. Evaporation provided a red powder, which was washed with Et<sub>2</sub>O (3 x 10 mL) to provide [RhCp\*(2-azidophenyl isonitrile)Cl<sub>2</sub>] as a red powder (107 mg, 0.24 mmol, 77.7%). [RhCp\*(2-azidophenyl isonitrile)Cl<sub>2</sub>] was stored as a solid in absence of light at -20 °C. Mp: 324 °C  $\leq$  decomp. <sup>1</sup>H NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  = 7.54-7.47 (m, 2H, *o*,*m*-Ar-*H*), 7.31 (d, <sup>3</sup>J<sub>H,H</sub> = 8.5 Hz, 1H, *m*-Ar-*H*), 7.21 (t, <sup>3</sup>J<sub>H,H</sub> = 7.6 Hz, 1H, *p*-Ar-*H*), 1.81 (s, 15H, Cp\*-CH<sub>3</sub>). <sup>13</sup>C {H}-NMR (125.78 MHz, CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  = 138.0 (s, *m*-Ar-*C*-N<sub>3</sub>), 131.7 (s, *o*-Ar-CH), 128.8 (s, *m*-Ar-CH), 125.8 (s, *m*-Ar-CH), 119.5 (s, *p*-Ar-CH), 101.1 (s, Cp\*-CCH<sub>3</sub>), 9.7 (s, Cp\*-CCH<sub>3</sub>), signals for Ar-CNC and Ar-CNC are unresolved. FT-IR: *v* = 3086 (w), 3013 (w), 3003 (w), 2966 (w), 2947 (w), 2918 (w), 2897 (w), 2353 (w), 2289 (w), 2176 (s), 2141 (s), 2125 (s), 2050 (w), 2029 (w), 1992 (w), 1979 (w), 1967 (w), 1952 (w), 1578 (w), 1560 (w), 1489 (s), 1472 (m), 1445 (m), 1406 (w), 1375 (w), 1358 (w), 1310 (s), 1292 (m), 1263 (w), 1219 (w), 1204 (w), 1148

<sup>&</sup>lt;sup>1</sup> Hahn, F.E.; Langenhahn, V.; Meier, N.; Lügger, T.; Fehlhammer, W.P. Chem. Eur. J., 2003, 9, 704–712.

<sup>&</sup>lt;sup>2</sup> Institut für Anorganische und Analytische Chemie, WWU Münster, Corrensstr. 28/30, D-48149 Münster, Germany.

<sup>&</sup>lt;sup>3</sup> R.G. Ball, W.A.G. Graham, D.M. Heinekey, J.K. Hoyano, A.D. McMaster, B.M. Mattson, S.T. Michel, Inorg. Chem., 1990, 29, 2023–2025.

<sup>&</sup>lt;sup>4</sup> B. Bostai, Z. Novák, A.C. Bényei, A. Kotschy, Org. Lett. 2007, 9, 3437–3439.

<sup>&</sup>lt;sup>5</sup> E. Çetinkaya, P.B. Hitchcock, H. Küçükbay, M.F. Lappert, S. Al-Juaid, J. Organomet. Chem., 1994, 481, 89-95.

<sup>&</sup>lt;sup>6</sup> O. Kaufhold, A. Flores-Figueroa, T. Pape, F.E. Hahn, Organometallics, 2009, 28, 896-901.

(m), 1092 (m), 1080 (m), 1040 (m), 1018 (m), 966 (w), 906 (w), 825 (w), 781 (s), 733 (m), 648 (m), 621 (w), 565 (m), 546 (m), 530 (m), 511 (w), 484 (w), 440 (w) cm<sup>-1</sup>. HRMS (ESI-Q-TOF): calcd for  $C_{17}H_{19}CIN_4Rh$ : 417.0348; found 417.0366.

### (1H-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) diiodide (4)

Alternative protocol 1: FeCl<sub>3</sub> (27 mg, 0.165 mmol, 1.5 eq.) was dissolved in acetonitrile (12 mL), after which NaI (150 mg, 1 mmol, 9.1 eq.) was added to provide a black suspension. Immediately afterwards, a solution of [(2-azidophenylisonitrile)IrCp\*Cl<sub>2</sub>] (60 mg, 0.11 mmol, 1.0 eq.) in DCM (3 mL) was added to the black suspension and the resulting mixture was stirred for 4h at RT. Volatiles (including iodine) were removed *in vacuo* to provide a black residue, which was extracted in DCM (40 mL) under atmospheric conditions. The dark extract was subsequently washed with a solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (100 mL, 20% in H<sub>2</sub>O) and NaHCO<sub>3</sub> (100 mL, saturated solution in H<sub>2</sub>O). The resulting orange solution was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation, [(1H-benzimidazolylidene)IrCp\*I<sub>2</sub>] was obtained as a dark yellow powder (48 mg, 0.07 mmol, 63%).

*Halogen exchange:* When a mixture of [(1H-benzimidazolylidene)IrCp\*I<sub>2</sub>] and [(1H-benzimidazolylidene)IrCp\*ICl] was obtained, the obtained mixture was dissolved in acetone (66 mL/mmol compound) to which excess NaI (approx. 3.0 eq.) was added. The resulting mixture was stirred for 72h at RT. Volatiles were removed *in vacuo* to yield a yellow residue, which was extracted in DCM (240 mL/mmol compound). Evaporation of the extract yielded [(1H-benzimidazolylidene)IrCp\*I<sub>2</sub>] as a yellow powder.

Alternative protocol 2: FeCl<sub>3</sub> (49 mg, 0.30 mmol, 1.5 eq.) and NaI (90 mg, 0.60 mmol, 3.0 eq.) were dissolved in acetone (30 mL) to provide a black suspension. Immediately afterwards, a solution of [(2-azidophenylisonitrile)IrCp\*I<sub>2</sub>] (147 mg, 0.20 mmol, 1.0 eq.) in DCM (6 mL) was added to the black suspension and the resulting mixture was stirred for 20h at RT. Volatiles (including iodine) were removed *in vacuo* to provide a very dark red residue, which was extracted in DCM (80 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (100 mL, 20% in H<sub>2</sub>O), a solution of Na<sub>1</sub>HCO<sub>3</sub> (100 mL, saturated solution in H<sub>2</sub>O) and brine (100 mL). The resulting orange solution was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation, [(1H-benzimidazolylidene)IrCp\*I<sub>2</sub>] was obtained as a dark yellow powder (96 mg, 0.14 mmol, 69%).

#### (x<sup>2</sup>-C,N-(acetimidoyl)-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) monoiodide (8)

Alternative protocol 1 / Control reaction 1: A red solution of FeCl<sub>3</sub> (28 mg, 0.17 mmol, 1.9 eq.) in MeCN (6 mL) was added to a colourless solution of NaI (137 mg, 0.91 mmol, 10.1 eq.) in MeCN (6 mL). The resulting black mixture was added to an orange solution of [(1H-benzimidazolylidene)IrCp\*I2] (63 mg, 0.09 mmol, 1.0 eq.) in DCM (3 mL). The resulting black mixture was stirred for 48h at RT. Volatiles (including iodine) were removed *in vacuo* to provide a black residue, which was extracted with DCM (35 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (50 mL, 20% in H<sub>2</sub>O) and NaHCO<sub>3</sub> (50 mL, saturated solution in H<sub>2</sub>O). The resulting yellow organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation and washing with CHCl<sub>3</sub> (2.5 mL), [( $\kappa^2$ -*C*,*N*-(acetimidoyl)-benzimidazolylidene)IrCp\*I] was obtained as a yellow powder (41 mg, 0.07 mmol, 74%).

Alternative protocol 2 / Control reaction 2: [(1H-benzimidazolylidene)IrCp\*I<sub>2</sub>] (6.5 mg, 0.0093 mmol, 1.2 eq.) was suspended in MeCN (2 mL) and refluxed for 5d. The resulting yellow solution was allowed to cool to RT and evaporated to provide [( $\kappa^2$ -C,N-1-(acetimino)-benzimidazolylidene) IrCp\*I<sub>2</sub>] as an oily orange-yellow solid, which then was dissolved in THF (3.9 mL) and cooled to -78 °C. A solution of DBU (0.1 mL of a 0.08M solution in THF, 1.0 eq.) in THF (0.1 mL) was added dropwise. The resulting yellow solution was allowed to warm to RT and was stirred for 60 min. Evaporation provided a yellow solid, which was washed with CHCl<sub>3</sub> (0.5 mL) to provide [( $\kappa^2$ -C,N-(acetimidoy])-benzimidazolylidene)IrCp\*I] as a light yellow powder (1.5 mg, 0.0026 mmol, 32%).

Control reaction 3: [(2-azidophenylisonitrile)IrCp\*I<sub>2</sub>] (90 mg, 0.12 mmol, 1.0 eq.) and NaI (190 mg, 1.27 mmol, 10.6 eq.) were dissolved in MeCN (13 mL) to provide a brown suspension. A red solution of FeCl<sub>3</sub> (36 mg, 0.22 mmol, 1.8 eq.) in MeCN (12 mL) was added to provide a very dark brown mixture which was stirred for 49h at RT. Volatiles (including iodine) were removed *in vacuo* to provide a black solid, which was extracted in DCM (2 x 30 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (60 mL, 20% in H<sub>2</sub>O) and NaHCO<sub>3</sub> (60 mL, saturated solution in H<sub>2</sub>O). The resulting orange solution was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to provide an orange solid, which was washed with CHCl<sub>3</sub> (10 mL), Et<sub>2</sub>O (20mL) and pentane (20 mL). <sup>1</sup>H-NMR analysis of the obtained orange solid (49 mg) revealed a mixture of  $[(\kappa^2-C,N-(acetimidoyl)-benzimidazolylidene)IrCp*I_]$  and  $[(1H-benzimidazolylidene)IrCp*I_2]$ .

# Bis ((1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III)) ( $\mu$ -hydrido) di( $\mu$ - $\kappa^2$ -*C*,*N*-1H-benzimidazolylidene) mono-chloride (9)

Alternative protocol 1 / Control reaction 1: [(1H-benzimidazolylidene)IrCp\*Cl<sub>2</sub>] (6.5 mg, 0.01 mmol, 1.0 eq.) was suspended in MeOH (1 mL) to provide an orange mixture, to which zinc dust (2 mg, 0.03 mmol, 3 eq.) and H<sub>2</sub>O (0.01 mL) were added. The mixture was stirred at reflux for 7d to provide an orange/red solution, which was allowed to cool to RT and was evaporated to provide a red solid. Under atmospheric conditions, the solid was extracted into CD<sub>2</sub>Cl<sub>2</sub> (3.0 mL), after which evaporation provided  $\mu$ - $\kappa^2$ -C,N-1H-benzimidazolylidene)<sub>2</sub>Ir<sub>2</sub>Cp\*<sub>2</sub>( $\mu$ -H)Cl] as a red solid (quant.).

Control reaction 2: [(2-azidophenylisonitrile)IrCp\*I<sub>2</sub>] (65 mg, 0.09 mmol, 1.0 eq.) was suspended in MeOH (20 mL) to provide an orange mixture, which was added over NH<sub>4</sub>Cl (13 mg, 0.24 mmol, 2.7 eq.) and zinc dust (10 mg, 0.15 mmol, 1.7 eq.). H<sub>2</sub>O (0.2 mL) was added and the suspension was stirred at reflux for 7d to provide a brown solution, which was allowed to cool to RT and was evaporated. Under atmospheric conditions, the brown solid was extracted in DCM (10 mL + 5 mL) and the combined extracts were evaporated to

3

provide an orange powder, which was washed with Et<sub>2</sub>O (15 mL) and pentane (15 mL). The powder was dissolved in DCM (20 mL) and washed with H<sub>2</sub>O (20 mL). Evaporation of the organic layer provided a red powder. <sup>1</sup>H-NMR analysis showed no  $[(\mu-\kappa^2-C,N-1H-benzimidazolylidene)_2Ir_2Cp*_2(\mu-H)X]$  formation.

Control reaction 3: [(1H-benzimidazolylidene)IrCp\*Cl<sub>2</sub>] (6.5 mg, 0.01 mmol, 1.0 eq.) was suspended in MeOH (1 mL) to provide an orange mixture, to which H<sub>2</sub>O (0.01 mL) was added. The mixture was stirred at reflux for 7d to provide an orange solution, which was allowed to cool to RT and evaporated to yield a red solid. <sup>1</sup>H-NMR analysis showed no [( $\mu$ - $\kappa^2$ -C,N-1H-benzimidazolylidene)<sub>2</sub>Ir<sub>2</sub>Cp\*<sub>2</sub>( $\mu$ -H)Cl] formation.

### Attempted synthesis (3-benzimidazolyl) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride

To a white suspension of benzimidazole (20 mg, 0.17 mmol, 3.4 eq.) in DCM (5 mL) was added  $[IrCp*Cl_2]_2$  (38 mg, 0.05 mmol, 1.0 eq.) to provide a yellow suspension, which was stirred for 2 days at RT. Evaporation yielded a yellow solid, which was washed with Et<sub>2</sub>O (3 x 2 mL) to provide a white-yellow solid (22 mg, 0.04 mmol, 44%). The extremely low solubility of the product prevented further identification.

# $\begin{array}{lll} Attempted & synthesis & bis((1,2,3,4,5-pentamethylcyclopentadienyl) & rhodium(III)) & (\mu-hydrido) \\ di(\mu-\kappa^2-C,N-1H-benzimidazolylidene) & monochloride \end{array}$

[(2-azidophenylisonitrile)RhCp\*Cl<sub>2</sub>] (56 mg, 0.12 mmol, 1.0 eq.), NH<sub>4</sub>Cl (26.2 mg, 0.49 mmol, 4.1 eq.) and zinc dust (20 mg, 0.30 mmol, 2.5 eq.) were combined in MeOH (15 mL) to give a red suspension, to which H<sub>2</sub>O (0.12 mL) was added. The resulting mixture was stirred at reflux for 164 hr to provide a red solution, which was allowed to cool to RT and was evaporated. The resulting red powder was washed with pentane (1 x 10 mL, 2 x 6 mL) and Et<sub>2</sub>O (2 x 10 mL). Under atmospheric conditions, the residue was dissolved in DCM (60 mL) and washed with H2O (3 x 60 mL, 1 x 40 mL). The organic layer was dried and evaporated to provide a red solid. <sup>1</sup>H-NMR analysis showed no bis((1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III)) ( $\mu$ -hydrido) di( $\mu$ -κ<sup>2</sup>-*C*,*N*-1H-benzimidazolylidene) monochloride) formation but a mixture of [(1H-benzimidazolylidene)RhCp\*Cl<sub>2</sub>] and unidentified side-products.

## Attemptedsynthesisbis((1-methyl-4-isopropyl-benzene)ruthenium(II))(μ-hydrido)di(μ-κ²-C,N-1H-benzimidazolylidene)monochloride

*Protocol 1:* [Ru(*p*-cymene)(2-azidophenylisonitrile)Cl<sub>2</sub>] (74 mg, 0.16 mmol, 1.0 eq.), NH<sub>4</sub>Cl (35 mg, 0.64 mmol, 4.0 eq.) and zinc dust (26 mg, 0.40 mmol, 2.5 eq.) were combined in MeOH (16 mL) to provide a yellow/brown suspension to which H<sub>2</sub>O (0.17 mL) was added. The mixture was stirred at reflux for 165 hr to provide a black suspension, which was allowed to cool to RT and was evaporated. Washing with Et<sub>2</sub>O (3 x 10 mL) provided a black powder (0% bis((1-methyl-4-isopropyl-benzene) ruthenium(II)) (μ-hydrido) di(μ-κ<sup>2</sup>-*C*,*N*-1H-benzimidazolylidene) monochloride). <sup>1</sup>H-NMR analysis revealed decomposition.

*Protocol 2:* [Ru(*p*-cymene)(2-azidophenylisonitrile)Cl<sub>2</sub>] (78 mg, 0.17 mmol, 1.0 eq.), NH<sub>4</sub>Cl (36 mg, 0.66 mmol, 3.9 eq.) and zinc dust (26 mg, 0.40 mmol, 2.4 eq.) were combined in MeOH (17 mL) to provide a yellow/brown suspension to which H<sub>2</sub>O (0.17 mL) was added. The mixture was stirred at RT for 164 hr to provide a black suspension, which was allowed to cool to RT and was evaporated. Washing with Et<sub>2</sub>O (3 x 10 mL) provided a black powder (0% bis((1-methyl-4-isopropyl-benzene) ruthenium(II)) ( $\mu$ -hydrido) di( $\mu$ -k<sup>2</sup>-*C*,*N*-1H-benzimidazolylidene) monochloride; partial formation of (1H-benzimidazolylidene) Ru(II)(*p*-cymene)Cl<sub>2</sub>;<sup>7</sup> HRMS (ESI-Q-TOF): calcd. for C<sub>17</sub>H<sub>22</sub>ClN<sub>2</sub>Ru: 391.0515; found: 391.0345).

<sup>7</sup> For the corresponding diiodo complex see: O. Kaufhold, A. Flores-Figueroa, T. Pape, F.E. Hahn, Organometallics, 2009, 28, 896.

## 2. NMR-spectra

### **General considerations**

NMR spectra were recorded on Bruker Avance 400 (<sup>1</sup>H, 400.13 MHz; <sup>13</sup>C{<sup>1</sup>H}, 100.61 MHz, room temperature) or a Bruker Avance 500 (<sup>1</sup>H, 500.23 MHz; <sup>13</sup>C{<sup>1</sup>H}, 125.78 MHz; room temperature). Chemical shifts are reported in ppm downfield from tetramethylsilane. <sup>1</sup>H-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  7.26) and CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  5.32). <sup>13</sup>C-spectra were internally referenced to residual solvent resonances: CDCl<sub>3</sub> ( $\delta$  5.84).



Figure S1. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 2.



Figure S2. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 2.



**Figure S3.** <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CDCl<sub>3</sub>) of complex **2**.



Figure S4. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 3.



Figure S5. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 3.



Figure S6. <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CDCl<sub>3</sub>) of complex 3.



Figure S7. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of (2-azidophenylisonitrile) (1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III) dichloride.



Figure S8. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of (2-azidophenylisonitrile) (1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III) dichloride.



Figure S9.  ${}^{13}C{}^{1}H$ -NMR (125.78 MHz, CDCl<sub>3</sub>) of (2-azidophenylisonitrile) (1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III) dichloride.



Figure S10. <sup>1</sup>H-NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 4.



Figure S11. Aromatic region  $^1\text{H-NMR}$  (500.23 MHz, CD\_2Cl\_2) of complex 4.



Figure S12.  $^{13}\mathrm{C}\{^{1}\mathrm{H}\}\text{-}\mathrm{NMR}$  (125.78 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 4.



Figure S13. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 5.



Figure S14. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 5.



Figure S15. <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 5.



Figure S16. <sup>1</sup>H-NMR (400.13 MHz, CDCl<sub>3</sub>) of (*N*,*N*'-dimethyl-2-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride.



**Figure S17.** Aromatic region <sup>1</sup>H-NMR (400.13 MHz, CDCl<sub>3</sub>) of (*N*,*N'*-dimethyl-2-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride.



Figure S18.  ${}^{13}C{}^{1}H$ -NMR (100.61 MHz, CDCl<sub>3</sub>) of (*N*,*N*'-dimethyl-2-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride.



Figure S19. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 6.



Figure S20. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 6.



Figure S21. <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CDCl<sub>3</sub>) of complex 6.



Figure S22. <sup>1</sup>H-NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 7.



Figure S23. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 7.



Figure S24. <sup>1</sup>H-NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 8.



Figure S25. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 8.



Figure S26. <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CD<sub>2</sub>Cl<sub>2</sub>) of complex 8.



Figure S27. <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 9.



Figure S28. Aromatic region <sup>1</sup>H-NMR (500.23 MHz, CDCl<sub>3</sub>) of complex 9.



Figure S29. <sup>13</sup>C{<sup>1</sup>H}-NMR (125.78 MHz, CDCl<sub>3</sub>) of complex 9.



Figure S30. Detail with Cp\*-NH correlations in NOESY (500.23 MHz, CDCl<sub>3</sub>) of complex 9.

### 3. Crystal structure determinations

The single-crystal X-ray diffraction studies of **3**, **4** and **6** were carried out on a Bruker-Nonius at 123(2) K using Mo-K $\alpha$  radiation ( $\lambda = 0.71073$  Å). Direct Methods or heavy atom methods (SHELXS-97)<sup>8</sup> were used for structure solution and refinement was carried out using SHELXL-2013 (full-matrix least-squares on  $F^2$ ).<sup>9</sup> Hydrogen atoms were localized by difference electron density determination and refined using a riding model (H(N) free). Semi-empirical absorption corrections were applied. For **3** an extinction correction was applied.

**3**: red crystals, C<sub>17</sub>H<sub>19</sub>I<sub>2</sub>IrN<sub>4</sub> · CH<sub>2</sub>Cl<sub>2</sub>,  $M_r = 810.29$ , crystal size  $0.30 \times 0.15 \times 0.12$  mm, monoclinic, space group  $P_{21/n}$  (No. 14), a = 9.463(1) Å, b = 11.757(1) Å, c = 20.717(2) Å,  $\beta = 95.26(1)^\circ$ , V = 2295.2(4) Å<sup>3</sup>, Z = 4,  $\rho = 2.345$  Mg/m<sup>-3</sup>,  $\mu$ (Mo-K<sub>a</sub>) = 8.75 mm<sup>-1</sup>, F(000) = 1496,  $2\theta_{max} = 55.0^\circ$ , 48478 reflections, of which 5259 were independent ( $R_{int} = 0.025$ ), 250 parameters,  $R_1 = 0.015$  (for 5061 I > 2 $\sigma$ (I)), w $R_2 = 0.032$  (all data), S = 1.19, largest diff. peak / hole = 0.52 / -0.59 e Å<sup>-3</sup>.

4: orange crystals, C<sub>17</sub>H<sub>21</sub>I<sub>2</sub>IrN<sub>2</sub>,  $M_r = 699.36$ , crystal size  $0.30 \times 0.10 \times 0.06$  mm, monoclinic, space group  $P2_1/c$  (No. 14), a = 9.703(1) Å, b = 11.875(1) Å, c = 16.439(2) Å,  $\beta = 90.10(1)^\circ$ , V = 1894.2(3) Å<sup>3</sup>, Z = 4,  $\rho = 2.452$  Mg/m<sup>3</sup>,  $\mu$ (Mo-K<sub>a</sub>) = 10.31 mm<sup>-1</sup>, F(000) = 1280,  $2\theta_{max} = 55.0^\circ$ , 24003 reflections, of which 4339 were independent ( $R_{int} = 0.052$ ), 210 parameters, 2 restraints,  $R_1 = 0.025$  (for 3812 I >  $2\sigma(I)$ ),  $wR_2 = 0.062$  (all data), S = 1.07, largest diff. peak / hole = 1.47 / -1.77 e Å<sup>-3</sup>.

**6**: red crystals, C<sub>19</sub>H<sub>25</sub>I<sub>2</sub>IrN<sub>2</sub>,  $M_r = 727.41$ , crystal size  $0.40 \times 0.20 \times 0.03$  mm, orthorhombic, space group *Pbca* (No. 61), a = 8.6423(6) Å, b = 17.5203(17) Å, c = 27.4808(18) Å, V = 4161.0(6) Å<sup>3</sup>, Z = 8,  $\rho = 2.322$  Mg/m<sup>-3</sup>,  $\mu$ (Mo-K<sub>a</sub>) = 9.39 mm<sup>-1</sup>, F(000) = 2688,  $2\theta_{max} = 55.0^{\circ}$ , 44349 reflections, of which 4776 were independent ( $R_{int} = 0.040$ ), 224 parameters,  $R_1 = 0.023$  (for 4295 I > 2 $\sigma$ (I)), w $R_2 = 0.054$  (all data), S = 1.08, largest diff. peak / hole = 1.98 / -1.16 e Å<sup>-3</sup>.

The single-crystal X-ray diffraction study of **9** was performed on a Bruker Kappa ApexII diffractometer with sealed tube and Triumph monochromator ( $\lambda = 0.71073$  Å) at a temperature of 150(2) K up to a resolution of (sin  $\lambda/\theta$ )max = 0.61 Å-1. The Eval15 software<sup>10</sup> was used for the intensity integration. For the prediction of reflection profiles a rather large isotropic mosaicity of 1.0 ° was used. A numerical absorption correction and scaling was performed with SADABS<sup>11</sup> (correction range 0.51-0.85). A total of 24638 reflections was measured, 13828 reflections were unique (R<sub>int</sub> = 0.028) leading to an overall completeness of 94.4%. 10816 reflections were observed [I>2 $\sigma$ (I)]. The structure was solved with Patterson superposition methods using SHELXT.<sup>12</sup> Structure refinement was performed with SHELXL-2018<sup>9</sup> on F<sup>2</sup> of all reflections. Two of the four independent solvent molecules were refined with disorder models. In these disorder components, three C atoms were refined isotropically. All other non-hydrogen atoms were refined freely with anisotropic displacement parameters. The hydrogen atoms were refined with a riding model. 918 Parameters were refined with 202 restraints (concerning distances, angles and displacement parameters in the CH<sub>2</sub>Cl<sub>2</sub> solvent). R1/wR2 [I > 2 $\sigma$ (I)]: 0.0370 / 0.0906. R1/wR2 [all refl.]: 0.0549 / 0.0983. S = 1.022. Residual electron density between -2.27 and 1.83 e/Å3. Geometry calculations and checking for higher symmetry was performed with the PLATON program.<sup>13</sup>

9:  $[C_{34}H_{41}Ir_2N_4]Cl \cdot 2 CH_2Cl_2$ , Fw = 1095.41, red needle,  $0.58 \times 0.11 \times 0.04 \text{ mm}^3$ , triclinic, P 1 (no. 2), a = 10.0193(6), b = 19.0273(8), c = 21.4413(11) Å,  $\alpha = 75.059(2)$ ,  $\beta = 86.963(2)$ ,  $\gamma = 85.500(3)$  °, V = 3935.0(3) Å<sup>3</sup>, Z = 4, D<sub>x</sub> = 1.849 g/cm<sup>3</sup>,  $\mu = 7.13 \text{ mm}^{-1}$ .

CCDC 1915713 (3), 1915714 (4), 1915715 (6) and 1921152 (9) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data request/cif.

<sup>&</sup>lt;sup>8</sup> G. M. Sheldrick, Acta Crystallogr., 2008, A64, 112-122.

<sup>&</sup>lt;sup>9</sup> G. M. Sheldrick, Acta Crystallogr., 2015, C71, 3-8.

<sup>&</sup>lt;sup>10</sup> A. M. M. Schreurs, X. Xian, L. M. J. Kroon-Batenburg. J. Appl. Cryst., 2010, 43, 70-82.

<sup>&</sup>lt;sup>11</sup> G. M. Sheldrick, **2014**. SADABS. Universität Göttingen, Germany.

<sup>&</sup>lt;sup>12</sup> G. M. Sheldrick. Acta Crystallogr., 2015, A71, 3-8.

<sup>&</sup>lt;sup>13</sup> A. L. Spek. Acta Crystallogr., 2009, D65, 148-155.



Figure S31. Molecular structure of 3 (solvent omitted for clarity, displacement parameters are drawn at 50% probability level)



Figure S32. Molecular structure of 4 (displacement parameters are drawn at 50% probability level)



Figure S33. Molecular structure of 6 (displacement parameters are drawn at 50% probability level)



Figure S34. Molecular structure of 9 (only one of two independent molecules is shown. Displacement parameters are drawn at 50% probability level).



Figure S35. Space-filling (CPK) plots of complexes 4 (left) and 6 (right) in orientations identical to Figure 4.

## 4. DFT calculations

## **Computational Procedures**

Density functional calculations were performed at the BP86/ZORA/Grimme-D3/TZ2P level of theory<sup>14</sup> using Amsterdam Density Functional (ADF)<sup>15</sup> 2013.01 (geometry optimizations, QTAIM<sup>16</sup>) and 2016.102 (ETS-NOCV<sup>17</sup>). The nature of each stationary point was confirmed by frequency calculations.

## Iridium-carbene bond analysis (ETS-NOCV)

	4	4	6
$\Delta E_{total}$	-67.8	-68.2	-62.7
$\Delta E_{Pauli}$	335.2	316.5	317.8
$\Delta E_{elstat}$	-271.7	-256.5	-255.2
$\Delta E_{orb}$	-131.4	-128.1	-125.3
σ	-90.6	-86.5	-82.6
$\pi_1$	-16.6	-17.2	-15.4
$\pi_2$	-6.9	-6.7	-8.2
polaris.	-9.4	-9.2	-9.0

<sup>&</sup>lt;sup>14</sup> a) E. van Lenthe, E.J. Baerends, *J. Comput. Chem.*, **2003**, *24*, 1142–1156. b) E. van Lenthe, E.J. Baerends, J.G. Snijders, *J. Chem. Phys.*, **1993**, *99*, 4597–4610. c) E. van Lenthe, E.J. Baerends, J.G. Snijders, *J. Chem. Phys.*, **1994**, *101*, 9783–9792. d) E. van Lenthe, A. Ehlers, E.J. Baerends, *J. Chem. Phys.*, **1999**, *110*, 8943–8953.

<sup>&</sup>lt;sup>15</sup> a) G. te Velde, F.M. Bickelhaupt, S.J.A. van Gisbergen, C. Fonseca Guerra, E.J. Baerends, J.G. Snijders, T. Ziegler, *J. Comput. Chem.*, **2009**, 22, 931–967. b) C. Fonseca Guerra, J.G. Snijders, G. te Velde, E.J. Baerends, *Theor. Chem. Acc.*, **1998**, *99*, 391–403. c) ADF2010/2013/2016, SCM, Theoretical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands, http://www.scm.com.

<sup>&</sup>lt;sup>16</sup> a) R.F.W. Bader, *Atoms In Molecules*, Claredon Press, Oxford, **1994**. b) J.I. Rodríguez, R.F.W. Bader, P.W. Ayers, C. Michel, A.W. Götz, C. Bo, *Chem. Phys. Lett.*, **2009**, 472, 149–152. c) J.I. Rodríguez, *J. Comput. Chem.*, **2013**, *34*, 681–686.

<sup>&</sup>lt;sup>17</sup> M.P. Mitoraj, A. Michalak, T. Ziegler, J. Chem. Theory Comput., 2009, 5, 962–975.

Dinuclear complex - QTAIM analysis



Figure S36. AIM analysis of bond paths in complex 9. Bond critical points in red, ring critical points in green, cage critical points in blue.

### Ir21-H1:

CP # 150

(RANK,SIGNATURE): (3,-1)

CP COORDINATES: 0.113662 -0.190354 -1.283076

### EIGENVALUES OF HESSIAN MATRIX:

-0.1266267E+00 -0.1176255E+00 0.3703199E+00

EIGENVECTORS (ORTHONORMAL) OF HESSIAN MATRIX (COLUMNS):

0.8894264E+00 -0.1517288E+00 -0.4311601E+00 0.4569990E+00 0.3127751E+00 0.8326606E+00 -0.8517573E-02 0.9376301E+00 -0.3475303E+00

VALUES OF SOME FUNCTIONS AT CP(a.u.):

Rho = 0.9650692E-01 |GRAD(Rho)| = 0.6368909E-15 GRAD(Rho)x = 0.2631921E-15 GRAD(Rho)y = -0.5744514E-15 GRAD(Rho)z = -0.7978459E-16 Laplacian = 0.1260677E+00 (-1/4)Del\*\*2(Rho)) = -0.3151691E-01

HESSIAN MATRIX:

-0.3403763E-01 -0.1788360E+00 0.7318250E-01 0.2187987E+00 -0.1411640E+00 -0.5869340E-01 lr11-H1:

CP COORDINATES: -0.357104 0.727128 -1.255170

#### EIGENVALUES OF HESSIAN MATRIX:

-0.1646005E+00 -0.1516453E+00 0.4353025E+00

EIGENVECTORS (ORTHONORMAL) OF HESSIAN MATRIX (COLUMNS):

-0.8838717E+000.2358074E+000.4039377E+00-0.4666449E+00-0.3857964E+00-0.7958666E+000.3183355E-010.8919395E+00-0.4510328E+00

VALUES OF SOME FUNCTIONS AT CP(a.u.):

 $\begin{array}{rll} Rho = & 0.1160140E+00 \\ |GRAD(Rho)| = & 0.1631405E-14 \\ GRAD(Rho)x = & 0.5493714E-15 \\ GRAD(Rho)y = & -0.1253037E-14 \\ GRAD(Rho)z = & -0.8885787E-15 \\ Laplacian = & 0.1190567E+00 \\ (-1/4)Del^{**}2(Rho)) = & -0.2976417E-01 \end{array}$ 

HESSIAN MATRIX:

-0.6599658E-01 -0.1940357E+00 -0.1065710E+00 0.2173085E+00 0.2108844E+00 -0.3225524E-01

### Ir11-H1-Ir21-N31-C81:

CP # 120 (RANK,SIGNATURE): (3,+1)

CP COORDINATES: 0.387311 0.400059 -0.299717

EIGENVALUES OF HESSIAN MATRIX:

-0.1888460E-01 0.5562107E-01 0.6427222E-01

EIGENVECTORS (ORTHONORMAL) OF HESSIAN MATRIX (COLUMNS):

-0.6544136E+00 -0.7415170E+00 -0.1479708E+00 -0.3165416E+00 0.9094018E-01 0.9442094E+00 0.6866908E+00 -0.6647424E+00 0.2942335E+00

VALUES OF SOME FUNCTIONS AT CP(a.u.):

 $\begin{array}{rcl} Rho = & 0.3057751E\text{-}01 \\ |GRAD(Rho)| = & 0.6053094E\text{-}16 \\ GRAD(Rho)x = & 0.2653959E\text{-}18 \\ GRAD(Rho)y = & -0.5651706E\text{-}16 \\ GRAD(Rho)z = & -0.2167363E\text{-}16 \\ Laplacian = & 0.1010087E\text{+}00 \\ (-1/4)Del^{**}2(Rho)) = & -0.2525217E\text{-}01 \end{array}$ 

## HESSIAN MATRIX:

0.2390290E-01 -0.1664249E-01 0.3310469E-01 0.5586848E-01 0.1859846E-01 0.2123731E-01

Ir11-H1-Ir21-N11-C11:

CP COORDINATES: -0.508760 -0.058241 -0.290503

EIGENVALUES OF HESSIAN MATRIX:

-0.1888377E-01 0.5538984E-01 0.6452279E-01

EIGENVECTORS (ORTHONORMAL) OF HESSIAN MATRIX (COLUMNS):

0.6523083E+00-0.3388319E+00-0.6780021E+000.3440975E+00-0.6646404E+000.6632119E+000.6753449E+000.6659175E+000.3169592E+00

VALUES OF SOME FUNCTIONS AT CP(a.u.):

 $\begin{array}{rcl} Rho = & 0.3054789E\text{-}01 \\ |GRAD(Rho)| = & 0.2719184E\text{-}13 \\ GRAD(Rho)x = & 0.2353707E\text{-}13 \\ GRAD(Rho)y = & -0.2062493E\text{-}15 \\ GRAD(Rho)z = & 0.1361469E\text{-}13 \\ Laplacian = & 0.1010289E\text{+}00 \\ (-1/4)Del^{**}2(Rho)) = & -0.2525721E\text{-}01 \end{array}$ 

HESSIAN MATRIX:

0.2798426E-01 -0.2077800E-01 -0.3468265E-01 0.5061274E-01 -0.1534019E-01 0.2243185E-01